> For the complete documentation index, see [llms.txt](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/bone-metastases/denosumab-and-zoledronic-acid.md). # Denosumab and Zoledronic Acid Denosumab and zoledronic acid are the two standard bone-targeted drugs most often discussed in metastatic cancer. Brand names can blur that comparison. Xgeva and Prolia are denosumab brands. Zometa is a zoledronic acid brand. Generic zoledronic acid is widely available. Denosumab biosimilars are also available in some markets. Both reduce skeletal-related events. They differ in mechanism, side-effect profile, and administration. ### How they compare | Parameter | Denosumab | Zoledronic acid | | ----------------------- | -------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------- | | Common brand names | Kmown as Xgeva (and Prolia in lower dosing contexts) | Zometa; generic zoledronic acid | | Mechanism | RANKL inhibitor and monoclonal antibody | Bisphosphonate that inhibits osteoclasts | | Skeletal-related events | Delays time to first skeletal-related event and was superior in some comparisons | Effective, but less so than denosumab in those comparisons | | Overall survival | Non-inferior to zoledronic acid | Comparable to denosumab | | Renal toxicity | Lower risk and no dose adjustment required in this comparison | Higher risk and requires monitoring | | Hypocalcaemia | Higher incidence | Lower incidence | | ONJ risk | Similar risk to zoledronic acid | Similar risk to denosumab | | Administration | Subcutaneous injection. Oncology schedules often use every 4 weeks. | IV infusion every 3 to 4 weeks, with some discussion of longer intervals in selected settings | ### Practical reading of the trade-off Denosumab is usually the more potent RANKL-directed option for delaying skeletal-related events. Zoledronic acid remains a major standard option, especially where cost, renal monitoring, rebound planning, or transition strategy matter. The choice is often less about one being universally better and more about side-effect trade-offs, monitoring burden, and treatment context. For upstream context on the same **RANKL** axis — including gut-immune signalling, **OPG**, aromatase-inhibitor bone loss, and why **L. reuteri** is being discussed alongside standard bone protection — see [L.reuteri hits RANKL/Bone Axis](/myhealingcommunity-docs/natural-medicines/terrain-support/l.-reuteri-in-oncology/l.reuteri-hits-rankl-bone-axis.md). ### Key References A randomised phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer\ Denosumab versus zoledronic acid in patients with bone metastases from solid tumours other than breast and prostate cancers or multiple myeloma\ Effect of denosumab versus zoledronic acid in patients with castrate-resistant prostate cancer and bone metastases\ Effects of denosumab versus zoledronic acid on pain in patients with metastatic breast cancer\ ### Bone metastasis hub pages * [Bone Metastases](/myhealingcommunity-docs/bone-metastases.md) * [Denosumab and Zoledronic Acid](/myhealingcommunity-docs/bone-metastases/denosumab-and-zoledronic-acid.md) * [Integrative and Off-Label Strategies](/myhealingcommunity-docs/bone-metastases/integrative-and-off-label-strategies.md) * [FOXM1 in Bone Metastasis](/myhealingcommunity-docs/bone-metastases/foxm1-in-bone-metastasis.md) * [Bone Support and Protocol Notes](/myhealingcommunity-docs/bone-metastases/bone-support-and-protocol-notes.md) * [Group Member Tips and Supporting Evidence](/myhealingcommunity-docs/bone-metastases/group-member-tips-and-supporting-evidence.md) ### Also relevant * [SABR for BC Bone Mets 2025 Study Summary](/myhealingcommunity-docs/bone-metastases/sabr-for-bone-metastases-2025-study-summary.md) --- # Agent Instructions This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com. ## Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter, and the optional `goal` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/bone-metastases/denosumab-and-zoledronic-acid.md?ask=&goal= ``` `ask` is the immediate question: it should be specific, self-contained, and written in natural language. `goal` is optional and describes the broader end goal you are ultimately trying to accomplish on behalf of the user. GitBook uses it to tailor the answer towards what is most useful for that goal. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.